<DOC>
	<DOCNO>NCT02911636</DOCNO>
	<brief_summary>Stereotactic Ablative Radiation ( SABR ) 35 Gy 5 fraction , weekly prostate simultaneous intraprostatic boost MR detect nodule 50Gy + 25 Gy 5 fraction , weekly simultaneously seminal vesicle ( SV 's ) pelvic lymph node + 6-18 month ADT</brief_summary>
	<brief_title>5 Fractions Pelvic SABR With Intra Prostatic SABR</brief_title>
	<detailed_description>SABR 25Gy / 5 fraction pelvis ; 35Gy / 5 fraction prostate ; 50Gy / 5 fraction MR nodule</detailed_description>
	<criteria>Histologically confirm prostate adenocarcinoma ( centrally review ) High tier intermediate risk define : PSA 1020ng/ml AND ( T2b2c OR Gleason 7 ) â€¢ Highrisk prostate cancer , define least one : T3 , OR Gleason 810 , OR PSA &gt; 20 ng/mL Willing give inform consent participate clinical trial Able willing complete Expanded Prostate Index Composite ( EPIC ) questionnaire Prior pelvic radiotherapy Contraindication radical prostate radiotherapy e.g . connective tissue disease inflammatory bowel disease Contraindication prostate MRI Anticoagulation medication ( unsafe discontinue gold seed insertion ) Diagnosis bleed diathesis Large prostate significant arch interference TRUS 3 month neoadjuvant ADT . Previous TURP Poor baseline urinary function define International Prostate Symptom Score ( IPSS ) &gt; 20 Significant medical comorbidity render patient unsuitable general anesthetic No evidence castrate resistance ( define PSA &lt; 3 ng/ml testosterone &lt; 0.7nmol/l . Patients could combine androgen blockade exclude start due PSA progression . Definitive extrapelvic nodal distant metastatic disease stag investigation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>